[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Godeau
B
B
D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010919:Placebos; D011446:Prospective Studies; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000276:immunology; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D011961:Receptors, Fc / Q000008:administration & dosage / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000187:drug effects*; D011993:Recombinant Fusion Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D013156:Splenectomy; D013921:Thrombocytopenia / Q000150:complications; D013926:Thrombopoietin; D013997:Time Factors
D000998:Antiviral Agents; D001565:Benzoates; D002352:Carrier Proteins; D006834:Hydrazines; D016756:Immunoglobulins, Intravenous; D010919:Placebos; D011720:Pyrazoles; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; D012254:Ribavirin; D007372:Interferons; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag